Validation of Boolean 2.0 criteria for remission and quality of life prediction in Korean patients with rheumatoid arthritis receiving targeted therapy
Authors' conclusion
Although Boolean 2.0 improves concordance with DAS28-ESR, it does not enhance the prediction of long-term functional or QoL outcomes.
Study context
- Population
- Korean patients with rheumatoid arthritis (RA) initiating JAKi or bDMARD treatment, multicentre prospective cohort414 completed 48 weeks
- Participants
- 506 patients
- Exposure
- Boolean 2.0 vs Boolean 1.0 remission definition
- Outcome
- Agreement (Cohen's kappa) of Boolean definitions with index-based remission criteria (DAS28-ESR, CDAI, SDAI); predictive validity of week-24 remission for week-48 HAQ-Disability Index (HAQ-DI) ≤0.5 and EQ-5D = 1
- Follow-up
- Week 24 remission; week 48 outcomes
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
Agreement with index-based remission criteria (Cohen's kappa)
- Boolean 2.0 showed stronger agreement with DAS28-ESR remission than Boolean 1.0 (κ = 0.50 vs. 0.39)
- Boolean 2.0 showed weaker agreement with Clinical Disease Activity Index (CDAI) than Boolean 1.0 (κ = 0.75 vs. 0.48, as printed)
- Boolean 2.0 showed weaker agreement with Simplified Disease Activity Index (SDAI) than Boolean 1.0 (κ = 0.76 vs. 0.64, as printed)
Observational data: associations, not effects.
Further findings
| Outcome | Boolean 2.0 | Boolean 1.0 |
|---|---|---|
| PPV of week-24 remission for HAQ-DI ≤0.5 · week 48 | ||
| PPV | 0.82 | 0.90 |
| PPV of week-24 remission for EQ-5D = 1 · week 48 | ||
| PPV | 0.30 | 0.38 |
Original publication
Validation of Boolean 2.0 criteria for remission and quality of life prediction in Korean patients with rheumatoid arthritis receiving targeted therapy. Rheumatology (Oxford). Published 30 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →